



## ASX ANNOUNCEMENT

**18 December 2015**

### **FDA Regulatory Progress Update – Conference Call Details**

Tissue Therapies Limited (ASX: TIS) released “FDA Regulatory Progress Update” on Thursday, 17 December 2015.

Dr Christian Behrenbruch, Executive Director will host a conference call to discuss the FDA Regulatory Progress Update at **10:00 a.m. Australian Eastern Standard Time (“AEST”) (i.e. 11:00 a.m. Australian Eastern Daylight Time (“AEDT”)) on Monday, 21 December 2015.**

#### **Conference Call Details**

Below is the conference call details. Please dial-in five minutes before the conference starts and provide your name and the Conference ID.

Conference ID: 1148 4244

Dial-in numbers:

- Australia toll-free: 1800 123 296
- Australia: +61 2 8038 5221
- United Kingdom: 0808 234 0757
- United States: 1855 293 1544

To ask a question, participants will need to dial “\*1” (star, 1) on the telephone keypad.

#### **Audio Stream**

The audio stream will be uploaded to Tissue Therapies’ website shortly after the conclusion of the call and can be accessed at any time.

- ENDS -

**For more information**

<p>Dr Christian P Behrenbruch, Ph.D Executive Director Tissue Therapies Limited Tel: +61 7 3334 3900 E-mail: <a href="mailto:c.behrenbruch@tissuetherapies.com">c.behrenbruch@tissuetherapies.com</a></p> <p>Dr Cherrell Hirst, Chairman Tissue Therapies Limited E-mail: <a href="mailto:Cherrell@hirst.com">Cherrell@hirst.com</a></p>	<p>Nigel Johnson, CEO Tissue Therapies Limited Tel: +61 7 3334 3900 E-mail: <a href="mailto:n.johnson@tissuetherapies.com">n.johnson@tissuetherapies.com</a></p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**About Tissue Therapies Limited**

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns.

Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company owns various patent families related to wound healing and other therapeutic uses. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges. For more information, please visit [www.tissuetherapies.com](http://www.tissuetherapies.com).